Premium
P1‐255: Cholinergic Enhancement Increases Regional Cerebral Blood Flow to The Posterior Cingulate Cortex in Mild Alzheimer’s Disease
Author(s) -
Iizuka Tomomichi,
Kameyama Masashi
Publication year - 2016
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2016.06.1004
Subject(s) - posterior cingulate , donepezil , cerebral blood flow , precuneus , cardiology , cholinergic , anterior cingulate cortex , medicine , psychology , cortex (anatomy) , neuroscience , cognition , disease , dementia
hemispheres. Data from 37 ROIs were entered into a principal component analysis. Sixty-two participants also underwent betaamyloid PET scans using either Pittsburgh Compound B (PiB) or Florbetapir (AV45) and were categorized as beta-amyloid positive or negative by a mean cortical SUVR cutoff. Results:Three components were identified, accounting for 83% of the binding variance. The first component (61% total variance) had positive loadings in the temporal, parietal, and occipital lobes, both lateral and medial surfaces. Component 2 was almost entirely comprised by the choroid plexus. Component 3 had positive loadings for the medial temporal lobes and negative for the posterior areas of component 1. Component 1 was higher in beta-amyloid positive participants. Component 2 correlated weakly with age. Component 3 was higher in the FTD cohort compared to the AD cohort. Conclusions: Our analysis showed three separate tau deposition processes. The first component was similar to the tau topography associated with preclinical AD and correlated well with beta-amyloid deposition. Component two was weakly associated with age, and was not associated with disease processes. The third component was higher in the FTD cohort than either cognitively normal or demented persons not in the FTD group. Additionally, differences were observed in component 3 between the differentMAPTmutation groups, though a larger number of participants is required for validation. F18-AV1451 precursor and technology was supported by Avid Radiopharmaceuticals. Research was funded by the NIH (UF1AG032438), the Barnes-Jewish Hospital Foundation and the Rainwater Charitable Foundation.